Envoy Medical, Inc 8-K, filed Nov 20, 2024
Envoy Medical, Inc. (COCH)
About this 8-K
Envoy Medical, Inc filed this 8-K on November 20, 2024, reporting on events of November 14, 2024.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including
area code: (
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The Stock Market LLC | ||||
| The Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On November 14, 2024, Envoy Medical, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”).
At the Annual Meeting:
| 1. | The Company’s stockholders (the “Stockholders”) elected two Class I director nominees to the Company’s Board of Directors to hold office until the earlier of the 2027 annual meeting of stockholders, the election of such director’s successor, or such director’s death, resignation or removal; |
| 2. | Stockholders ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024; |
| 3. | Stockholders approved, on a non-binding and advisory basis, the compensation of the Company’s named executive officers; and |
| 4. | Stockholders recommended, on a non-binding and advisory basis, a one-year frequency of votes on named executive officer compensation. |
The voting results for each such matter were as follows:
| 1. | Election of directors: |
| Nominee: | For: | Withheld: | Broker Non-Votes: | |||
| Michael Crowe | 11,146,464 | 20,254 | 2,030,681 | |||
| Mona Patel | 11,047,146 | 119,572 | 2,030,681 |
| 2. | Ratification of the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024: |
| For: | Against: | Abstain: | ||
| 13,173,556 | 12,662 | 11,181 |
| 3. | Approval, on a non-binding and advisory basis, of the Company’s named executive officer compensation: |
| For: | Against: | Abstain: | Broker Non-Votes: | |||
| 11,117,644 | 29,673 | 19,401 | 2,030,681 |
| 4. | Recommendation, on a non-binding and advisory basis, of a one-year frequency of votes on named executive officer compensation. |
| 1 year | 2 years | 3 years | Abstain | Broker Non-Votes: | ||||
| 11,135,620 | 11,789 | 3,139 | 16,170 | 2,030,681 |
In light of stockholder approval at the Annual Meeting to hold an advisory vote on the compensation of the Company’s named executive officers every year, the Company’s Board of Directors has determined to hold an advisory vote on the compensation of the Company’s named executive officers every year, until the next advisory vote on the frequency of future advisory votes on the compensation of the Company’s named executive officers or until the Board of Directors otherwise determines that a different frequency for such advisory vote would be in the best interests of the Company’s stockholders.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ENVOY MEDICAL, INC. | ||
| November 20, 2024 | By: | /s/ David R. Wells |
| David R. Wells | ||
| Chief Financial Officer | ||
2